Page 183 - MI-2-3

Microbes & Immunity A novel anti-EphB2 monoclonal antibody for flow cytometry

doi: 10.1038/s41568-023-00634-x doi: 10.3390/ijms24033015
4. Anderton M, Van der Meulen E, Blumenthal MJ, Schäfer G. 15. Psilopatis I, Souferi-Chronopoulou E, Vrettou K,
The Role of the eph receptor family in tumorigenesis. Troungos C, Theocharis S. EPH/Ephrin-targeting treatment
Cancers (Basel). 2021;13(2):206. in breast cancer: A new chapter in breast cancer therapy. Int
doi: 10.3390/cancers13020206 J Mol Sci. 2022;23(23):15275.
5. Liang LY, Patel O, Janes PW, Murphy JM, Lucet IS. Eph doi: 10.3390/ijms232315275
receptor signalling: From catalytic to non-catalytic 16. Psilopatis I, Pergaris A, Vrettou K, Tsourouflis G,
functions. Oncogene. 2019;38(39):6567-6584. Theocharis S. The EPH/Ephrin system in gynecological
doi: 10.1038/s41388-019-0931-2 cancers: Focusing on the roots of carcinogenesis for better
patient management. Int J Mol Sci. 2022;23(6):3249.
6. Pasquale EB. Eph receptors and ephrins in cancer:
Bidirectional signalling and beyond. Nat Rev Cancer. doi: 10.3390/ijms23063249
2010;10(3):165-180. 17. Psilopatis I, Karniadakis I, Danos KS, et al. May EPH/ephrin
doi: 10.1038/nrc2806 targeting revolutionize lung cancer treatment? Int J Mol Sci.
2022;24(1):93.
7. Pasquale EB. Eph receptor signalling casts a wide net on cell
behaviour. Nat Rev Mol Cell Biol. 2005;6(6):462-475. doi: 10.3390/ijms24010093
doi: 10.1038/nrm1662 18. Papadakos SP, Petrogiannopoulos L, Pergaris A,
Theocharis S. The EPH/ephrin system in colorectal cancer.
8. Arora S, Scott AM, Janes PW. Eph receptors in cancer. Int J Mol Sci. 2022;23(5):2761.
Biomedicines. 2023;11(2):315.
doi: 10.3390/ijms23052761
doi: 10.3390/biomedicines11020315
19. Liu W, Yu C, Li J, Fang J. The roles of EphB2 in cancer. Front
9. Lau A, Le N, Nguyen C, Kandpal RP. Signals transduced Cell Dev Biol. 2022;10:788587.
by Eph receptors and ephrin ligands converge on MAP
kinase and AKT pathways in human cancers. Cell Signal. doi: 10.3389/fcell.2022.788587
2023;104:110579. 20. Chen X, Yu D, Zhou H, et al. The role of EphA7 in different
doi: 10.1016/j.cellsig.2022.110579 tumors. Clin Transl Oncol. 2022;24(7):1274-1289.
10. Toracchio L, Carrabotta M, Mancarella C, Morrione A, doi: 10.1007/s12094-022-02783-1
Scotlandi K. EphA2 in cancer: molecular complexity and 21. Goparaju C, Donington JS, Hsu T, Harrington R, Hirsch N,
therapeutic opportunities. Int J Mol Sci. 2024;25(22):12191. Pass HI. Overexpression of EPH receptor B2 in malignant
doi: 10.3390/ijms252212191 mesothelioma correlates with oncogenic behavior. J Thorac
Oncol. Sep 2013;8(9):1203-1211.
11. Scarini JF, Gonçalves MWA, De Lima-Souza RA, et al.
Potential role of the Eph/ephrin system in colorectal doi: 10.1097/JTO.0b013e31829ceb6a
cancer: Emerging druggable molecular targets. Front Oncol. 22. Cha JH, Chan LC, Wang YN, et al. Ephrin receptor A10
2024;14:1275330. monoclonal antibodies and the derived chimeric antigen
doi: 10.3389/fonc.2024.1275330 receptor T cells exert an antitumor response in mouse
models of triple-negative breast cancer. J Biol Chem.
12. Guo X, Yang Y, Tang J, Xiang J. Ephs in cancer progression: 2022;298(4):101817.
Complexity and context-dependent nature in signaling,
angiogenesis and immunity. Cell Commun Signal. doi: 10.1016/j.jbc.2022.101817
2024;22(1):299. 23. Xiao T, Xiao Y, Wang W, Tang YY, Xiao Z, Su M. Targeting
doi: 10.1186/s12964-024-01580-3 EphA2 in cancer. J Hematol Oncol. 2020;13(1):114.
13. Stergiou IE, Papadakos SP, Karyda A, Tsitsilonis OE, doi: 10.1186/s13045-020-00944-9
Dimopoulos MA, Theocharis S. EPH/Ephrin signaling 24. Tang FHF, Davis D, Arap W, Pasqualini R, Staquicini FI. Eph
in normal hematopoiesis and hematologic malignancies: receptors as cancer targets for antibody-based therapy. Adv
Deciphering their intricate role and unraveling possible new Cancer Res. 2020;147:303-317.
therapeutic targets. Cancers (Basel). 2023;15(15):3963.
doi: 10.1016/bs.acr.2020.04.007
doi: 10.3390/cancers15153963
25. London M, Gallo E. Critical role of EphA3 in cancer
14. Papadakos SP, Dedes N, Gkolemi N, Machairas N,
Theocharis S. The EPH/Ephrin system in pancreatic ductal and current state of EphA3 drug therapeutics. Mol Biol
adenocarcinoma (PDAC): From pathogenesis to treatment. Rep. 2020;47(7):5523-5533.
Int J Mol Sci. 2023;24(3):3015. doi: 10.1007/s11033-020-05571-8

Volume 2 Issue 3 (2025) 175 doi: 10.36922/mi.5728